Nyxoah SA
Develops & commercializes implantable neurostimulation therapy for severe Obstructive Sleep Apnea.
NYXH | BR
Overview
Corporate Details
- ISIN(s):
- BE0974358906
- LEI:
- 5493002O1ESKZ18OXR80
- Country:
- Belgium
- Address:
- Rue Edouard Belin 12, 1435 Mont-Saint-Guibert
- Website:
- https://www.nyxoah.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of irradiation, electromedical and electrotherapeutic equipment
Description
Nyxoah SA is a commercial-stage medical technology company focused on the development and commercialization of innovative solutions for Obstructive Sleep Apnea (OSA). The company's lead product is the Genio® system, an implantable neurostimulation therapy designed to treat patients with moderate to severe OSA. The system works by providing bilateral stimulation to the hypoglossal nerve, which controls the tongue muscles, thereby keeping the airway open during sleep. It is intended as a therapeutic alternative for patients who cannot tolerate or have failed traditional Continuous Positive Airway Pressure (CPAP) therapy.
This is a Fraction of the Available Data.
You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Nyxoah SA and 9,000+ other companies.
Stop analyzing yesterday's news. Start building a real-time advantage.
Request Enterprise API AccessFilings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-09-15 22:40 |
Legal Proceedings Report
Nyxoah Files Patent Infringement Lawsuit Against Inspire Medical Systems, Inc.
|
English | 10.7 KB | |
| 2025-08-29 22:30 |
Major Shareholding Notification
2025 08 29 - Press release - Number of shares (ENG).pdf
|
English | 522.4 KB | |
| 2025-08-29 22:30 |
Major Shareholding Notification
2025 08 29 - Press release - Number of shares (FR).pdf
|
French | 521.0 KB | |
| 2025-08-18 22:10 |
Earnings Release
ENGLISH_Q2 2025 Earnings PR_FINAL.pdf
|
English | 316.1 KB | |
| 2025-08-18 22:10 |
Earnings Release
FRENCH_Q2 2025 Earnings PR_FINAL.pdf
|
French | 310.1 KB | |
| 2025-08-18 22:10 |
Interim Report
Q2 2025 financial report (Euronext) (ENG) (final).pdf
|
English | 800.2 KB | |
| 2025-08-18 22:10 |
Interim Report
Q2 2025 financial report (Euronext) (FR) (final).pdf
|
French | 803.6 KB | |
| 2025-08-18 22:10 |
Earnings Release
Nyxoah Reports Second Quarter Financial and Operating Results
|
English | 55.6 KB | |
| 2025-08-11 07:00 |
Earnings Release
Nyxoah Announces Preliminary Results for the Second Quarter of 2025
|
English | 14.8 KB | |
| 2025-08-08 23:30 |
Regulatory News Service
Nyxoah Receives Approval from FDA for Genio System for the Treatment of Obstruc…
|
English | 12.9 KB | |
| 2025-08-08 22:10 |
Regulatory News Service
ENGLISH_FDA APPROVAL PRESS RELEASE - FINAL.pdf
|
English | 156.0 KB | |
| 2025-08-08 22:10 |
Regulatory News Service
FRENCH_FDA APPROVAL PRESS RELEASE - FINAL.pdf
|
French | 166.1 KB | |
| 2025-07-29 22:45 |
Declaration of Voting Results & Voting Rights Announcements
2025 07 29 - Press release - Number of shares (ENG).pdf
|
English | 136.6 KB | |
| 2025-07-29 22:45 |
Declaration of Voting Results & Voting Rights Announcements
2025 07 29 - Press release - Number of shares (FR).pdf
|
French | 136.0 KB | |
| 2025-07-28 22:05 |
Legal Proceedings Report
Nyxoahs DREAM Pivotal Study Data Published in the Journal of Clinical Sleep Med…
|
English | 14.7 KB |
Automate Your Workflow. Get a real-time feed of all Nyxoah SA filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Nyxoah SA via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-11-19 | Laurette Renard | Close relation | Sell | 5,000 | 39,000.00 EUR |
| 2024-09-05 | Hambrecht Jürgen | Board | Sell | 980,000 | 6,840,400.00 EUR |
| 2024-09-05 | JH Capital GmbH | Close relation | Buy | 980,000 | 6,840,400.00 EUR |
| 2024-01-25 | Tompkins Patrick | Executive member | Buy | 2,000 | 18,020.00 USD |
| 2023-12-28 | Onkelinx Bruno | Executive member | Buy | 470 | 2,035.10 EUR |
| 2023-08-18 | Moreau Loïc | Executive member | Buy | 6,427 | 48,416.52 EUR |
| 2023-08-14 | Moreau Loïc | Executive member | Buy | 3,800 | 28,697.60 EUR |
| 2023-08-11 | Moreau Loïc | Executive member | Buy | 3,000 | 21,957.60 EUR |
| 2023-07-04 | Wildman Ventures LLC | Board | Buy | 25,000 | N/A |
| 2023-07-02 | Gianello Pierre | Board | Buy | 25,000 | N/A |
